Leading global science-led biopharmaceutical company AstraZeneca announced its decision of further investing $90 million over the next 5 years in India.
The announcement was made following the signature of the bilateral innovation partnership for a sustainable future between Sweden and India.
This investment commitment will span across AstraZeneca’s diverse footprint in India with an aim to strengthen its manufacturing, clinical operations, patient safety & regulatory science, IT services and commercial operations. Furthermore this investment will support scientific data generation, quality manufacturing, science talent development and collaborative development of innovative solutions to improve the standard of care of non-communicable diseases in India.
AstraZeneca Pharma India is the operating company covering manufacturing, sales and marketing activities. It has an innovative portfolio to address the unmet needs in non-communicable diseases such as diabetes, heart disease, cancer, asthma and Chronic Obstructive Pulmonary Disease (COPD).